Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor.

Autor: Kesteleyn B; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Bonfanti JF; Janssen Infectious Diseases Discovery, Janssen-Cilag, Chaussée du Vexin, Val de Reuil 27106, France., Bardiot D; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium., De Boeck B; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Goethals O; Janssen Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Kaptein SJF; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Leuven 3000, Belgium., Stoops B; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Coesemans E; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Fortin J; Janssen Infectious Diseases Discovery, Janssen-Cilag, Chaussée du Vexin, Val de Reuil 27106, France., Muller P; Janssen Infectious Diseases Discovery, Janssen-Cilag, Chaussée du Vexin, Val de Reuil 27106, France., Doublet F; Janssen Infectious Diseases Discovery, Janssen-Cilag, Chaussée du Vexin, Val de Reuil 27106, France., Carlens G; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium., Koukni M; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium., Smets W; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium., Raboisson P; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Chaltin P; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Bioincubator 2, Gaston Geenslaan 2, Leuven 3000, Belgium., Simmen K; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Loock MV; Janssen Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium., Neyts J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Leuven 3000, Belgium.; Global Virus Network (GVN), Baltimore, Maryland 21201, United States., Marchand A; CISTIM Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, Leuven 3001, Belgium., Jonckers THM; Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Mar 14; Vol. 67 (5), pp. 4063-4082. Date of Electronic Publication: 2024 Feb 28.

Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.

Autor: Goethals O; Janssen Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium., Kaptein SJF; Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium., Kesteleyn B; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Bonfanti JF; Janssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.; Galapagos, Romainville, France., Van Wesenbeeck L; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Bardiot D; Cistim Leuven vzw, Leuven, Belgium., Verschoor EJ; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Verstrepen BE; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Fagrouch Z; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Putnak JR; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Kiemel D; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany., Ackaert O; Janssen Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutica NV, Beerse, Belgium., Straetemans R; Statistics and Decision Sciences, Janssen Pharmaceutica NV, Beerse, Belgium., Lachau-Durand S; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Geluykens P; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.; Discovery, Charles River Beerse, Beerse, Belgium., Crabbe M; Statistics and Decision Sciences, Janssen Pharmaceutica NV, Beerse, Belgium., Thys K; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Stoops B; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Lenz O; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Tambuyzer L; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., De Meyer S; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Dallmeier K; Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium., McCracken MK; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gromowski GD; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Rutvisuttinunt W; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Jarman RG; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Karasavvas N; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Touret F; Unité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France., Querat G; Unité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France., de Lamballerie X; Unité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France., Chatel-Chaix L; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.; Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, Quebec, Canada., Milligan GN; Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA., Beasley DWC; Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA., Bourne N; Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA., Barrett ADT; Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA., Marchand A; Cistim Leuven vzw, Leuven, Belgium., Jonckers THM; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium., Raboisson P; Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.; Galapagos NV, Mechelen, Belgium., Simmen K; Johnson & Johnson Innovation, London, UK., Chaltin P; Cistim Leuven vzw, Leuven, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium., Bartenschlager R; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.; German Centre for Infection Research, Heidelberg Partner Site, Heidelberg, Germany., Bogers WM; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Neyts J; Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Van Loock M; Janssen Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium. mvloock@its.jnj.com.

Publikováno v: Nature [Nature] 2023 Mar; Vol. 615 (7953), pp. 678-686. Date of Electronic Publication: 2023 Mar 15.

Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.

Autor: Kaptein SJF; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium., Goethals O; Janssen Global Public Health, Janssen Pharmaceutica, Beerse, Belgium., Kiemel D; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany., Marchand A; Cistim Leuven, Leuven, Belgium., Kesteleyn B; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Bonfanti JF; Janssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.; Galapagos, Romainville, France., Bardiot D; Cistim Leuven, Leuven, Belgium., Stoops B; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Jonckers THM; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Dallmeier K; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium., Geluykens P; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.; Charles River Beerse, Discovery, Beerse, Belgium., Thys K; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Crabbe M; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Chatel-Chaix L; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.; Institut National de la Recherche Scientifique, Centre Armand-Frappier Santé Biotechnologie, Quebec, Quebec, Canada., Münster M; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany., Querat G; Unité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France., Touret F; Unité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France., de Lamballerie X; Unité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France., Raboisson P; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.; Aligos, Leuven, Belgium., Simmen K; Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Chaltin P; Cistim Leuven, Leuven, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium., Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.; German Center for Infection Research, Heidelberg Partner Site, Heidelberg, Germany., Van Loock M; Janssen Global Public Health, Janssen Pharmaceutica, Beerse, Belgium. mvloock@its.jnj.com., Neyts J; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. johan.neyts@kuleuven.be.; Global Virus Network (GVN), Baltimore, MD, USA. johan.neyts@kuleuven.be.

Publikováno v: Nature [Nature] 2021 Nov; Vol. 599 (7883), pp. E2.

Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate.

Autor: Milanole G, Andriessen F, Lemonnier G, Sebban M, Coadou G, Couve-Bonnaire S, Bonfanti JF, Jubault P, Pannecoucke X

Publikováno v: Organic letters [Org Lett] 2015 Jun 19; Vol. 17 (12), pp. 2968-71. Date of Electronic Publication: 2015 Jun 08.